<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Front Psychiatry</journal-id><journal-id journal-id-type="pmc-domain-id">1463</journal-id><journal-id journal-id-type="pmc-domain">frontpsychiat</journal-id><journal-id journal-id-type="publisher-id">Front. Psychiatry</journal-id><journal-title-group><journal-title>Frontiers in Psychiatry</journal-title></journal-title-group><issn pub-type="epub">1664-0640</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11178937</article-id><article-id pub-id-type="pmcid-ver">PMC11178937.1</article-id><article-id pub-id-type="pmcaid">11178937</article-id><article-id pub-id-type="pmcaiid">11178937</article-id><article-id pub-id-type="pmid">38883846</article-id><article-id pub-id-type="doi">10.3389/fpsyt.2023.1308245</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Psychiatry</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Alcohol abuse may increase the risk of autoimmune connective tissue disease: a nationwide population-based cohort study</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Chang</surname><given-names initials="CC">Chi-Chen</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn0001" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Wang</surname><given-names initials="CT">Chia-Ti</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn0001" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shih</surname><given-names initials="HM">Hong-Mo</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ho</surname><given-names initials="CH">Chung-Han</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/536247/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hsu</surname><given-names initials="CC">Chien-Chin</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lin</surname><given-names initials="HJ">Hung-Jung</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref><xref rid="aff8" ref-type="aff">
<sup>8</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Chiu</surname><given-names initials="YW">Yen-Wei</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2537047/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Huang</surname><given-names initials="CC">Chien-Cheng</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref><xref rid="aff9" ref-type="aff">
<sup>9</sup>
</xref><xref rid="aff10" ref-type="aff">
<sup>10</sup>
</xref><xref rid="c002" ref-type="corresp">
<sup>*</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Emergency Medicine, Chi Mei Medical Center</institution>, <addr-line>Tainan</addr-line>, <country>Taiwan</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Emergency Medicine, China Medical University Hospital</institution>, <addr-line>Taichung</addr-line>, <country>Taiwan</country></aff><aff id="aff3"><sup>3</sup><institution>School of Medicine, College of Medicine, China Medical University</institution>, <addr-line>Taichung</addr-line>, <country>Taiwan</country></aff><aff id="aff4"><sup>4</sup><institution>Department of Public Health, China Medical University</institution>, <addr-line>Taichung</addr-line>, <country>Taiwan</country></aff><aff id="aff5"><sup>5</sup><institution>Department of Medical Research, Chi Mei Medical Center</institution>, <addr-line>Tainan</addr-line>, <country>Taiwan</country></aff><aff id="aff6"><sup>6</sup><institution>Department of Information Management, Southern Taiwan University of Science and Technology</institution>, <addr-line>Tainan</addr-line>, <country>Taiwan</country></aff><aff id="aff7"><sup>7</sup><institution>School of Medicine, College of Medicine, National Sun Yat-sen University</institution>, <addr-line>Kaohsiung</addr-line>, <country>Taiwan</country></aff><aff id="aff8"><sup>8</sup><institution>Department of Emergency Medicine, Taipei Medical University</institution>, <addr-line>Taipei</addr-line>, <country>Taiwan</country></aff><aff id="aff9"><sup>9</sup><institution>Department of Emergency Medicine, Kaohsiung Medical University</institution>, <addr-line>Kaohsiung</addr-line>, <country>Taiwan</country></aff><aff id="aff10"><sup>10</sup><institution>Department of Environmental and Occupational Health, College of Medicine, National Cheng Kung University</institution>, <addr-line>Tainan</addr-line>, <country>Taiwan</country></aff><author-notes><fn id="fn0002" fn-type="edited-by"><p>Edited by: Alessio Simonetti, Fondazione Policlinico Universitario &#8220;Agostino Gemelli&#8221; IRCCS, Italy</p></fn><fn id="fn0003" fn-type="edited-by"><p>Reviewed by: Nami Mohammadian Khonsari, Alborz University of Medical Sciences, Iran</p><p>Ya-Yun Cheng, National Sun Yat-sen University, Taiwan</p></fn><corresp id="c001">*Correspondence: Yen-Wei Chiu, <email>u9922410@cmu.edu.tw</email></corresp><corresp id="c002">Chien-Cheng Huang, <email>jasonhuang0803@gmail.com</email></corresp><fn id="fn0001" fn-type="equal"><p><sup>&#8224;</sup>These authors have contributed equally to this work</p></fn></author-notes><pub-date pub-type="epub"><day>01</day><month>6</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>14</volume><issue-id pub-id-type="pmc-issue-id">427509</issue-id><elocation-id>1308245</elocation-id><history><date date-type="received"><day>10</day><month>10</month><year>2023</year></date><date date-type="accepted"><day>26</day><month>12</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>06</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>15</day><month>06</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-17 17:25:15.950"><day>17</day><month>06</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2024 Chang, Wang, Shih, Ho, Hsu, Lin, Chiu and Huang.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Chang, Wang, Shih, Ho, Hsu, Lin, Chiu and Huang</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fpsyt-14-1308245.pdf"/><abstract><sec id="sec1"><title>Objectives</title><p>Altered immune and inflammatory responses resulting from alcohol abuse have been implicated in increasing the risk of autoimmune connective tissue disease (ACTD). However, limited research has been conducted on this topic in the Asian population. Therefore, this study was undertaken to investigate and address this knowledge gap.</p></sec><sec id="sec2"><title>Methods</title><p>Using data from Taiwan&#8217;s National Health Insurance Research Database, we identified all patients with alcohol abuse between 2000 and 2017. We selected a comparison cohort without alcohol abuse, matching them in terms of age, sex, and index date at a 3:1 ratio. We collected information on common underlying comorbidities for analysis. Both cohorts were followed up until the diagnosis of ACTD or the end of 2018.</p></sec><sec id="sec3"><title>Results</title><p>A total of 57,154 patients with alcohol abuse and 171,462 patients without alcohol abuse were included in the study. The age and sex distributions were similar in both cohorts, with men accounting for 89.8% of the total. After adjusting for underlying comorbidities, patients with alcohol abuse had a higher risk of developing ACTD [adjusted hazard ratio (AHR): 1.12, 95% confidence interval (CI): 1.01&#8211;1.25]. The stratified analysis revealed that this increased risk was specific to the male population. Additionally, besides alcohol abuse, liver disease, renal disease, coronary artery disease, and chronic obstructive pulmonary disease were identified as independent predictors for ACTD.</p></sec><sec id="sec4"><title>Conclusion</title><p>This study demonstrates that alcohol abuse increases the risk of developing ACTD in the Asian population, particularly among men. Therefore, it is important to implement alcohol cessation, especially in individuals with liver disease, renal disease, coronary artery disease, and chronic obstructive pulmonary disease.</p></sec></abstract><kwd-group><kwd>alcohol abuse</kwd><kwd>Asian</kwd><kwd>autoimmune connective tissue disease</kwd><kwd>male</kwd><kwd>Taiwan</kwd></kwd-group><funding-group><funding-statement>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by grant number CMHCR10954 from the Chi Mei Medical Center.</funding-statement></funding-group><counts><fig-count count="1"/><table-count count="3"/><equation-count count="0"/><ref-count count="25"/><page-count count="7"/><word-count count="4752"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Addictive Disorders</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec5"><label>1</label><title>Introduction</title><p>Autoimmune connective tissue diseases (ACTDs) encompass a diverse group of chronic inflammatory conditions affecting various organs (<xref rid="ref1" ref-type="bibr">1</xref>). These diseases exhibit global prevalence and can affect individuals of all races (<xref rid="ref2" ref-type="bibr">2</xref>). Incidence rates vary, with a higher occurrence observed during adolescence and the 20s (<xref rid="ref2" ref-type="bibr">2</xref>). Mixed connective tissue disease, specific subsets of ACTDs, have variable annual occurrence rates in different countries, typically ranging from 0.21 to 1.9 cases per 100,000 adults (<xref rid="ref2" ref-type="bibr">2</xref>). ACTDs demonstrate sex disparities, primarily affecting women (<xref rid="ref2" ref-type="bibr">2</xref>). Reported sex ratios vary significantly, ranging from 3.3:1 up to 16:1 (<xref rid="ref2" ref-type="bibr">2</xref>). ACTDs have a multifactorial etiology involving genetic, environmental, and immunological factors (<xref rid="ref3" ref-type="bibr">3</xref>). Alcohol consumption has been suggested as a potential contributing factor to the development of ACTDs (<xref rid="ref3" ref-type="bibr">3</xref>).</p><p>Alcohol abuse is a significant public health problem worldwide, with an estimated 3.3 million deaths attributable to its harmful use in 2016 alone (<xref rid="ref4" ref-type="bibr">4</xref>). In addition to its well-known effects on liver, cardiovascular, and neurological systems, alcohol abuse has been linked to immune dysfunction, including alterations in cytokine profiles and impaired immune cell function (<xref rid="ref5" ref-type="bibr">5</xref>, <xref rid="ref6" ref-type="bibr">6</xref>). These immunomodulatory effects of alcohol have raised concerns about its possible association with autoimmune disorders.</p><p>While there is an increasing body of literature indicating a potential association between alcohol consumption and autoimmune disorders, including ACTDs, the available evidence remains inconclusive, with a lack of studies focusing on this issue in the Asian population. To address this gap, we conducted a nationwide population-based cohort study to examine the potential risk of ACTDs among individuals with alcohol abuse. Our study aims to enhance the current knowledge regarding the potential link between alcohol abuse and ACTDs, as well as shed light on the underlying mechanisms that may contribute to this association.</p></sec><sec sec-type="methods" id="sec6"><label>2</label><title>Methods</title><sec id="sec7"><label>2.1</label><title>Data source</title><p>We collected data from the National Health Insurance Research Database (NHIRD), derived from Taiwan&#8217;s single-payer compulsory National Health Insurance program, covering up to 99% of the 23 million Taiwanese population (<xref rid="ref7" ref-type="bibr">7</xref>). The NHIRD contains information on the dates of inpatient and outpatient visits, medical diagnosis, expenditure, and prescription details (<xref rid="ref7" ref-type="bibr">7</xref>). All entries are linked by a unique personal identifier number; hence, the medical utilization and registration records could be obtained for each enrollee (<xref rid="ref7" ref-type="bibr">7</xref>).</p></sec><sec id="sec8"><label>2.2</label><title>Study design, setting, and participants</title><p>Alcohol abuse is recognized as a disease in Taiwan when it leads to changes in the brain and contributes to significant physical and mental health issues (<xref rid="ref8" ref-type="bibr">8</xref>). These may include conditions such as liver disease, cardiovascular problems, cognitive impairment, and psychiatric disorders (<xref rid="ref8" ref-type="bibr">8</xref>). The seriousness of alcohol abuse cases seeking help in hospitals in Taiwan, as in any other region, can vary widely depending on factors such as the severity of the individual&#8217;s alcohol use disorder, the presence of co-occurring health issues, and the overall impact on the person&#8217;s life (<xref rid="ref8" ref-type="bibr">8</xref>). In our study, alcohol abuse was operationalized according to the diagnostic codes outlined by the International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] (291, 305.0, 303.0, 303.9, 357.5, 425.5, 535.3, 571.0&#8211;571.3, 655.4, or 760.71) or ICD-10 (F10.3&#8211;F10.9, F10.0, F10.1, F10.2, G62.1, G31.2, G72.1, I42.6, K29.2, K70&#8211;K70.4, K70.9, Q86.0, P04.3, O35.4, or K86.0). A patient was diagnosed as an alcohol abuser if they were above the age of 20&#8201;years and had received at least one diagnosis from the specified ICD codes during a hospitalization. The study cohort comprised all patients above the age of 20&#8201;years who met the criteria for alcohol abuse (<xref rid="fig1" ref-type="fig">Figure 1</xref>). The index date was defined as the date when the patients were diagnosed as alcohol abusers. Through the index date, we then identified patients without alcohol abuse as comparison cohort by matching age and sex at a ratio of 1:3. Patients who had ACTD (ICD-9-CM 710, 714 or ICD-10&#8201;M30&#8211;M36) in both cohorts before the index date were excluded.</p><fig position="float" id="fig1" orientation="portrait"><label>Figure 1</label><caption><p>Flowchart of this study. NHIRD, National Health Insurance Research Database; ACTD, autoimmune connective tissue disease.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fpsyt-14-1308245-g001.jpg"/></fig></sec><sec id="sec9"><label>2.3</label><title>Definitions of variables</title><p>We classified the collected patients into four subgroups as follows: aged 20&#8211;34, 35&#8211;49, 50&#8211;64, and&#8201;&#8805;65&#8201;years (<xref rid="ref9" ref-type="bibr">9</xref>). The underlying comorbidities were identified as follows: smoking (ICD-9-CM 305.1; ICD-10 Z72.0), diabetes (ICD-9-CM: 250; ICD-10 E08&#8211;E13), herpes zoster (ICD-9-CM: 053; ICD-10: B02), hepatitis (ICD-9-CM: 070; ICD-10: B15&#8211;B19), HIV infection (ICD-9-CM: 042, 079.53; ICD-10: B20&#8211;B24), liver disease (ICD-9-CM: 570&#8211;576; ICD-10: K70&#8211;K77), renal disease (ICD-9-CM: 580&#8211;593; ICD-10: N17&#8211;N19), malignancy (ICD-9-CM: 140&#8211;208; ICD-10: C00&#8211;C96, D00&#8211;D09), hypertension (ICD-9-CM: 401&#8211;405; ICD-10: I10&#8211;I16), hyperlipidemia (ICD-9-CM: 272; ICD-10: E78.5), coronary artery disease (CAD; ICD-9-CM: 410&#8211;414; ICD-10: I20&#8211;I25), congestive heart failure (CHF; ICD-9-CM: 428; ICD-10: I50), and chronic obstructive pulmonary disease (COPD; ICD-9-CM: 496; ICD-10: J44). The underlying comorbidities were defined as being diagnosed at least during one hospitalization or at three outpatient visits.</p></sec><sec id="sec10"><label>2.4</label><title>Outcome measures</title><p>The primary outcome measure was defined as ACTD development during the follow-up period. ACTD was identified by using the ICD-9-CM of 710 or 714 or ICD-10-CM of M30&#8211;M36 with at least one hospitalization. All patients were followed from the index date until the development of the ACTD, death, or until 31 December 2018.</p></sec><sec id="sec11"><label>2.5</label><title>Ethical statements</title><p>The study was conducted in accordance with the World Medical Association Declaration of Helsinki. This study was approved by the Institutional Review Board of the Chi-Mei Medical Center. As the data collected from NHIRD have been de-identified, the need for informed consent was waived.</p></sec><sec id="sec12"><label>2.6</label><title>Statistical analyses</title><p>We used the Pearson chi-square test and independent <italic toggle="yes">t</italic>-test to analyze categorical and continuous variables between the two cohorts. Considering the time until events occur in a cohort study, univariate and multivariate Cox proportional hazards regression analyses were performed to estimate the risk of ACTD between the alcohol abuse cohort and comparison cohort. Stratified analyses were performed according to age, sex, and underlying comorbidities to investigate potential effect modification. We also performed Cox proportional hazard regression analyses in all patients to investigate independent predictors for ACTD. All statistical analyses were performed using SAS 9.4 for Windows (SAS Institute, Cary, NC, United States). A value of <italic toggle="yes">p</italic> of &lt;0.05 indicated significance (two-tailed).</p></sec></sec><sec sec-type="results" id="sec13"><label>3</label><title>Results</title><sec id="sec14"><label>3.1</label><title>Patient characteristics</title><p>In this study, a total of 57,154 patients with alcohol abuse and 171,462 patients without alcohol abuse were included (<xref rid="tab1" ref-type="table">Table 1</xref>). There were no significant differences between these two cohorts in terms of age and sex distributions. The largest proportion of patients belonged to the age subgroup of 35&#8211;49&#8201;years (43.2%), followed by 50&#8211;64&#8201;years (34.6%), 20&#8211;34&#8201;years (11.7%), and&#8201;&#8805;&#8201;65&#8201;years (10.5%). In both cohorts, male patients constituted the majority, accounting for 89.8% of the total population. Comparing the two cohorts, patients with alcohol abuse exhibited a higher prevalence of smoking, hepatitis, and liver disease. Conversely, they had a lower prevalence of conditions such as herpes zoster, HIV infection, renal disease, malignancy, CAD, and COPD than those without alcohol abuse.</p><table-wrap position="float" id="tab1" orientation="portrait"><label>Table 1</label><caption><p>Comparison of demographic characteristics and underlying comorbidities between alcohol abuse and non-alcohol abuse cohorts through univariate analysis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Variables</th><th align="center" valign="top" rowspan="1" colspan="1">Alcohol abuse <italic toggle="yes">n</italic>&#8201;=&#8201;57,154</th><th align="center" valign="top" rowspan="1" colspan="1">Non-alcohol abuse <italic toggle="yes">n</italic>&#8201;=&#8201;171,462</th><th align="center" valign="top" rowspan="1" colspan="1">Value of <italic toggle="yes">p</italic></th></tr></thead><tbody><tr><td align="left" valign="middle" colspan="4" rowspan="1">
<bold>Age (years)</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">20&#8211;34</td><td align="center" valign="middle" rowspan="1" colspan="1">6,661 (11.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">19,983 (11.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">&gt;0.999</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">35&#8211;49</td><td align="center" valign="middle" rowspan="1" colspan="1">24,674 (43.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">74,022 (43.2)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">50&#8211;64</td><td align="center" valign="middle" rowspan="1" colspan="1">19,795 (34.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">59,385 (34.6)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8805;65</td><td align="center" valign="middle" rowspan="1" colspan="1">6,024 (10.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">18,072 (10.5)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" colspan="4" rowspan="1">
<bold>Sex</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Female</td><td align="center" valign="middle" rowspan="1" colspan="1">5,813 (10.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">17,439 (10.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">&gt;0.999</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Male</td><td align="center" valign="middle" rowspan="1" colspan="1">51,341 (89.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">154,023 (89.8)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" colspan="4" rowspan="1">
<bold>Underlying comorbidity</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Smoking</td><td align="center" valign="middle" rowspan="1" colspan="1">367 (0.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">941 (0.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.010</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Diabetes</td><td align="center" valign="middle" rowspan="1" colspan="1">6,729 (11.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">20,187 (11.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">&gt;0.999</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Herpes zoster</td><td align="center" valign="middle" rowspan="1" colspan="1">166 (0.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">958 (0.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Hepatitis</td><td align="center" valign="middle" rowspan="1" colspan="1">3,805 (6.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">6,855 (4.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HIV infection</td><td align="center" valign="middle" rowspan="1" colspan="1">85 (0.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">535 (0.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Liver disease</td><td align="center" valign="middle" rowspan="1" colspan="1">14,061 (24.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">14,606 (8.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Renal disease</td><td align="center" valign="middle" rowspan="1" colspan="1">2,948 (5.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">14,151 (8.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Malignancy</td><td align="center" valign="middle" rowspan="1" colspan="1">3,166 (5.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">13,705 (8.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Hypertension</td><td align="center" valign="middle" rowspan="1" colspan="1">10,269 (18.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">30,807 (18.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">&gt;0.999</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Hyperlipidemia</td><td align="center" valign="middle" rowspan="1" colspan="1">4,105 (7.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">12,315 (7.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">&gt;0.999</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CAD</td><td align="center" valign="middle" rowspan="1" colspan="1">1,862 (3.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">9,526 (5.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CHF</td><td align="center" valign="middle" rowspan="1" colspan="1">930 (1.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">2,759 (1.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.766</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">COPD</td><td align="center" valign="middle" rowspan="1" colspan="1">562 (1.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">2,213 (1.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr></tbody></table><table-wrap-foot><p>Data are expressed as means&#8201;&#177;&#8201;SD or <italic toggle="yes">n</italic> (%). SD, standard deviation; HIV, human immunodeficiency virus; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; ACTD, autoimmune connective tissue disease.</p></table-wrap-foot></table-wrap></sec><sec id="sec15"><label>3.2</label><title>Comparison of two cohorts: overall analysis and stratified analyses by age, sex, and underlying comorbidity</title><p>In the overall analysis, patients with alcohol abuse exhibited a higher risk of developing ACTD than those without alcohol abuse, even after adjusting for variables that showed a significant difference in the crude analysis [adjusted hazard ratio (AHR): 1.12; 95% confidence interval (CI): 1.01&#8211;1.25, <italic toggle="yes">p</italic>&#8201;=&#8201;0.037; <xref rid="tab2" ref-type="table">Table 2</xref>]. Stratified analyses further revealed that the increased risk of ACTD associated with alcohol abuse was specifically observed in the male population (AHR: 1.17; 95% CI: 1.03&#8211;1.32, <italic toggle="yes">p</italic>&#8201;=&#8201;0.016). However, no significant difference was found in other subgroups, including women and individuals with various underlying comorbidities included in this study.</p><table-wrap position="float" id="tab2" orientation="portrait"><label>Table 2</label><caption><p>Comparison of ACTD risk between alcohol abuse and non-alcohol abuse cohorts: Cox proportional hazard regression analysis and stratified analyses by age, sex, and underlying comorbidity.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="2" colspan="1">Variables</th><th align="center" valign="top" colspan="2" rowspan="1">Alcohol abuse</th><th align="center" valign="top" colspan="2" rowspan="1">Non-alcohol abuse</th><th align="center" valign="top" rowspan="2" colspan="1">Crude HR (95% CI)</th><th align="center" valign="top" rowspan="2" colspan="1">Value of <italic toggle="yes">p</italic></th><th align="center" valign="top" rowspan="2" colspan="1">AHR (95% CI)<sup>*</sup></th><th align="center" valign="top" rowspan="2" colspan="1">Value of <italic toggle="yes">p</italic></th></tr><tr><th align="center" valign="top" rowspan="1" colspan="1">Patients, <italic toggle="yes">n</italic></th><th align="center" valign="top" rowspan="1" colspan="1">ACTD, <italic toggle="yes">n</italic> (%)</th><th align="center" valign="top" rowspan="1" colspan="1">Patients, <italic toggle="yes">n</italic></th><th align="center" valign="top" rowspan="1" colspan="1">ACTD, <italic toggle="yes">n</italic> (%)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Overall analysis</td><td align="center" valign="middle" rowspan="1" colspan="1">57,154</td><td align="center" valign="middle" rowspan="1" colspan="1">506 (0.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">171,462</td><td align="center" valign="middle" rowspan="1" colspan="1">1,538 (0.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.14 (1.03&#8211;1.26)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.012</td><td align="center" valign="middle" rowspan="1" colspan="1">1.12 (1.01&#8211;1.25)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.037</td></tr><tr><td align="left" valign="middle" colspan="9" rowspan="1">
<bold>Stratified analysis</bold>
</td></tr><tr><td align="left" valign="middle" colspan="9" rowspan="1">
<bold>Age (years)</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">20&#8211;34</td><td align="center" valign="middle" rowspan="1" colspan="1">6,661</td><td align="center" valign="middle" rowspan="1" colspan="1">37 (0. 6)</td><td align="center" valign="middle" rowspan="1" colspan="1">19,983</td><td align="center" valign="middle" rowspan="1" colspan="1">121 (0.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.10 (0.76&#8211;1.61)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.611</td><td align="center" valign="middle" rowspan="1" colspan="1">1.02 (0.69&#8211;1.51)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.910</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">35&#8211;49</td><td align="center" valign="middle" rowspan="1" colspan="1">24,674</td><td align="center" valign="middle" rowspan="1" colspan="1">205 (0.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">74,022</td><td align="center" valign="middle" rowspan="1" colspan="1">569 (0.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.23 (1.04&#8211;1.45)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.014</td><td align="center" valign="middle" rowspan="1" colspan="1">1.19 (1.00&#8211;1.41)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.052</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">50&#8211;64</td><td align="center" valign="middle" rowspan="1" colspan="1">19,795</td><td align="center" valign="middle" rowspan="1" colspan="1">202 (1.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">59,385</td><td align="center" valign="middle" rowspan="1" colspan="1">633 (1.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.14 (0.97&#8211;1.35)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.114</td><td align="center" valign="middle" rowspan="1" colspan="1">1.11 (0.94&#8211;1.32)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.234</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8805;65</td><td align="center" valign="middle" rowspan="1" colspan="1">6,024</td><td align="center" valign="middle" rowspan="1" colspan="1">62 (1.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">18,072</td><td align="center" valign="middle" rowspan="1" colspan="1">215 (1.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00 (0.74&#8211;1.35)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.990</td><td align="center" valign="middle" rowspan="1" colspan="1">1.05 (0.76&#8211;1.45)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.771</td></tr><tr><td align="left" valign="middle" colspan="9" rowspan="1">
<bold>Sex</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Female</td><td align="center" valign="middle" rowspan="1" colspan="1">5,813</td><td align="center" valign="middle" rowspan="1" colspan="1">100 (1.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">17,439</td><td align="center" valign="middle" rowspan="1" colspan="1">333 (1.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.05 (0.84&#8211;1.32)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.670</td><td align="center" valign="middle" rowspan="1" colspan="1">0.98 (0.77&#8211;1.25)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.886</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Male</td><td align="center" valign="middle" rowspan="1" colspan="1">51,341</td><td align="center" valign="middle" rowspan="1" colspan="1">406 (0.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">154,023</td><td align="center" valign="middle" rowspan="1" colspan="1">1,205 (0.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.18 (1.05&#8211;1.33)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.005</td><td align="center" valign="middle" rowspan="1" colspan="1">1.16 (1.03&#8211;1.31)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.016</td></tr><tr><td align="left" valign="middle" colspan="9" rowspan="1">
<bold>Underlying comorbidity</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Smoking</td><td align="center" valign="middle" rowspan="1" colspan="1">367</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (1.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">941</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (1.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Diabetes</td><td align="center" valign="middle" rowspan="1" colspan="1">6,729</td><td align="center" valign="middle" rowspan="1" colspan="1">65 (1.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">20,187</td><td align="center" valign="middle" rowspan="1" colspan="1">191 (1.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.29 (0.95&#8211;1.74)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.102</td><td align="center" valign="middle" rowspan="1" colspan="1">1.27 (0.93&#8211;1.74)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.138</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Herpes zoster</td><td align="center" valign="middle" rowspan="1" colspan="1">166</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (1.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">958</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (1.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Hepatitis</td><td align="center" valign="middle" rowspan="1" colspan="1">3,805</td><td align="center" valign="middle" rowspan="1" colspan="1">42 (1.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">6,855</td><td align="center" valign="middle" rowspan="1" colspan="1">66 (1.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HIV infection</td><td align="center" valign="middle" rowspan="1" colspan="1">85</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">535</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (0.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Liver disease</td><td align="center" valign="middle" rowspan="1" colspan="1">14,061</td><td align="center" valign="middle" rowspan="1" colspan="1">126 (0.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">14,606</td><td align="center" valign="middle" rowspan="1" colspan="1">177 (1.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.07 (0.67&#8211;1.72)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.778</td><td align="center" valign="middle" rowspan="1" colspan="1">1.21 (0.73&#8211;2.00)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.464</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Renal disease</td><td align="center" valign="middle" rowspan="1" colspan="1">2,948</td><td align="center" valign="middle" rowspan="1" colspan="1">24 (0.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">14,151</td><td align="center" valign="middle" rowspan="1" colspan="1">158 (1.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.91 (0.33&#8211;2.53)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.863</td><td align="center" valign="middle" rowspan="1" colspan="1">0.87 (0.27&#8211;2.84)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.819</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Malignancy</td><td align="center" valign="middle" rowspan="1" colspan="1">3,166</td><td align="center" valign="middle" rowspan="1" colspan="1">28 (0.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">13,705</td><td align="center" valign="middle" rowspan="1" colspan="1">109 (0.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">4.70 (0.52&#8211;42.78)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.170</td><td align="center" valign="middle" rowspan="1" colspan="1">4.14 (0.17&#8211;103.37)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.387</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Hypertension</td><td align="center" valign="middle" rowspan="1" colspan="1">10,269</td><td align="center" valign="middle" rowspan="1" colspan="1">127 (1.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">30,807</td><td align="center" valign="middle" rowspan="1" colspan="1">344 (1.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.26 (1.02&#8211;1.56)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.035</td><td align="center" valign="middle" rowspan="1" colspan="1">1.18 (0.94&#8211;1.48)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.165</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Hyperlipidemia</td><td align="center" valign="middle" rowspan="1" colspan="1">4,105</td><td align="center" valign="middle" rowspan="1" colspan="1">54 (1.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">12,315</td><td align="center" valign="middle" rowspan="1" colspan="1">132 (1.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.36 (0.98&#8211;1.88)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.066</td><td align="center" valign="middle" rowspan="1" colspan="1">1.31 (0.92&#8211;1.86)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.130</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CAD</td><td align="center" valign="middle" rowspan="1" colspan="1">1,862</td><td align="center" valign="middle" rowspan="1" colspan="1">25 (1.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">9,526</td><td align="center" valign="middle" rowspan="1" colspan="1">130 (1.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.05 (0.45&#8211;2.46)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.913</td><td align="center" valign="middle" rowspan="1" colspan="1">0.70 (0.22&#8211;2.18)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.533</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CHF</td><td align="center" valign="middle" rowspan="1" colspan="1">930</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (1.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">2,759</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (0.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">COPD</td><td align="center" valign="middle" rowspan="1" colspan="1">562</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (1.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">2,213</td><td align="center" valign="middle" rowspan="1" colspan="1">34 (1.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>ATCD, autoimmune connective tissue disease; HR, hazard ratio; CI, confidence interval; HIV, human immunodeficiency virus; AHR, adjusted hazard ratio; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease. <sup>*</sup>Adjusted for variables with a significant difference in the crude analysis.</p></table-wrap-foot></table-wrap></sec><sec id="sec16"><label>3.3</label><title>Independent predictors of ACTD in all participants</title><p>In addition to alcohol abuse, other factors independently associated with an increased risk of ACTD included liver disease (AHR: 1.32; 95% CI: 1.12&#8211;1.56, <italic toggle="yes">p</italic>&#8201;=&#8201;0.001), renal disease (AHR: 1.21; 95% CI: 1.00&#8211;1.47), CAD (AHR: 1.30; 95% CI: 1.04&#8211;1.62, <italic toggle="yes">p</italic>&#8201;=&#8201;0.020), and COPD (AHR: 1.64; 95% CI: 1.08&#8211;2.49, <italic toggle="yes">p</italic>&#8201;=&#8201;0.022; <xref rid="tab3" ref-type="table">Table 3</xref>).</p><table-wrap position="float" id="tab3" orientation="portrait"><label>Table 3</label><caption><p>Independent predictors of ACTD in all participants by a Cox proportional hazard regression analysis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Variables</th><th align="center" valign="top" rowspan="1" colspan="1">Patients, <italic toggle="yes">n</italic></th><th align="center" valign="top" rowspan="1" colspan="1">ACTD, <italic toggle="yes">n</italic> (%)</th><th align="center" valign="top" rowspan="1" colspan="1">Crude HR (95% CI)</th><th align="center" valign="top" rowspan="1" colspan="1">Value of <italic toggle="yes">p</italic></th><th align="center" valign="top" rowspan="1" colspan="1">AHR (95% CI)*</th><th align="center" valign="top" rowspan="1" colspan="1">Value of <italic toggle="yes">p</italic></th></tr></thead><tbody><tr><td align="left" valign="top" colspan="7" rowspan="1">
<bold>Cohort</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Alcohol abuse</td><td align="center" valign="top" rowspan="1" colspan="1">57,154</td><td align="center" valign="top" rowspan="1" colspan="1">506 (0.9)</td><td align="center" valign="top" rowspan="1" colspan="1">1.14 (1.03&#8211;1.26)</td><td align="center" valign="top" rowspan="1" colspan="1">0.012</td><td align="center" valign="top" rowspan="1" colspan="1">1.12 (1.01&#8211;1.25).</td><td align="center" valign="top" rowspan="1" colspan="1">0.037</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Non-alcohol abuse</td><td align="center" valign="top" rowspan="1" colspan="1">171,462</td><td align="center" valign="top" rowspan="1" colspan="1">1,538 (0.9)</td><td align="center" valign="top" rowspan="1" colspan="1">1.00 (reference)</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1.00 (reference)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" colspan="7" rowspan="1">
<bold>Underlying comorbidity</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Smoking</td><td align="center" valign="middle" rowspan="1" colspan="1">1,308</td><td align="center" valign="middle" rowspan="1" colspan="1">15 (1.2)</td><td align="center" valign="top" rowspan="1" colspan="1">1.37 (0.83&#8211;2.28)</td><td align="center" valign="top" rowspan="1" colspan="1">0.221</td><td align="center" valign="top" rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Herpes zoster</td><td align="center" valign="middle" rowspan="1" colspan="1">1,124</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (1.2)</td><td align="center" valign="top" rowspan="1" colspan="1">1.49 (0.86&#8211;2.56)</td><td align="center" valign="top" rowspan="1" colspan="1">0.154</td><td align="center" valign="top" rowspan="1" colspan="1">0.89 (0.46&#8211;1.71)</td><td align="center" valign="top" rowspan="1" colspan="1">0.717</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Hepatitis</td><td align="center" valign="middle" rowspan="1" colspan="1">10,660</td><td align="center" valign="middle" rowspan="1" colspan="1">108 (1.0)</td><td align="center" valign="top" rowspan="1" colspan="1">1.46 (1.20&#8211;1.77)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">1.20 (0.93&#8211;1.55)</td><td align="center" valign="top" rowspan="1" colspan="1">0.165</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HIV infection</td><td align="center" valign="middle" rowspan="1" colspan="1">620</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (0.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.79 (0.30&#8211;2.11)</td><td align="center" valign="top" rowspan="1" colspan="1">0.643</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Liver disease</td><td align="center" valign="middle" rowspan="1" colspan="1">28,667</td><td align="center" valign="middle" rowspan="1" colspan="1">303 (1.1)</td><td align="center" valign="top" rowspan="1" colspan="1">1.53 (1.35&#8211;1.73)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">1.32 (1.12&#8211;1.56)</td><td align="center" valign="top" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Renal disease</td><td align="center" valign="middle" rowspan="1" colspan="1">17,099</td><td align="center" valign="middle" rowspan="1" colspan="1">182 (1.1)</td><td align="center" valign="top" rowspan="1" colspan="1">1.35 (1.16&#8211;1.57)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">1.21 (1.00&#8211;1.47)</td><td align="center" valign="top" rowspan="1" colspan="1">0.050</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Malignancy</td><td align="center" valign="middle" rowspan="1" colspan="1">16,871</td><td align="center" valign="middle" rowspan="1" colspan="1">137 (0.8)</td><td align="center" valign="top" rowspan="1" colspan="1">1.47 (1.23&#8211;1.75)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">1.12 (0.90&#8211;1.40)</td><td align="center" valign="top" rowspan="1" colspan="1">0.297</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CAD</td><td align="center" valign="middle" rowspan="1" colspan="1">11,388</td><td align="center" valign="middle" rowspan="1" colspan="1">155 (1.4)</td><td align="center" valign="top" rowspan="1" colspan="1">1.68 (1.43&#8211;1.98)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">1.30 (1.04&#8211;1.62)</td><td align="center" valign="top" rowspan="1" colspan="1">0.020</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CHF</td><td align="center" valign="middle" rowspan="1" colspan="1">3,689</td><td align="center" valign="middle" rowspan="1" colspan="1">25 (0.7)</td><td align="center" valign="top" rowspan="1" colspan="1">1.01 (0.68&#8211;1.50)</td><td align="center" valign="top" rowspan="1" colspan="1">0.950</td><td align="center" valign="top" rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">COPD</td><td align="center" valign="middle" rowspan="1" colspan="1">2,775</td><td align="center" valign="middle" rowspan="1" colspan="1">43 (1.6)</td><td align="center" valign="top" rowspan="1" colspan="1">2.40 (1.78&#8211;3.25)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">1.64 (1.08&#8211;2.49)</td><td align="center" valign="top" rowspan="1" colspan="1">0.022</td></tr></tbody></table><table-wrap-foot><p>ATCD, autoimmune connective tissue disease; HR, hazard ratio; CI, confidence interval; HIV, human immunodeficiency virus; AHR, adjusted hazard ratio; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease. <sup>*</sup>Adjusted for variables with a significant difference in the crude analysis.</p></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" id="sec17"><label>4</label><title>Discussion</title><p>This study demonstrated that patients with alcohol abuse had an increased risk of developing ACTD than those without alcohol abuse, particularly among men. Furthermore, apart from alcohol abuse, liver disease, renal disease, CAD, and COPD were identified as independent predictors for ACTD.</p><p>Notably, the initial alcohol abuse cohort highlighted a decreased prevalence of diseases, including herpes zoster, HIV infection, renal disease, malignancy, CAD, and COPD, when compared to individuals without alcohol abuse (<xref rid="tab1" ref-type="table">Table 1</xref>). Reviewing the previous literature utilizing NHIRD, Chen and colleagues enrolled individuals with alcohol use disorder to investigate the risk of mesenteric ischemia (<xref rid="ref10" ref-type="bibr">10</xref>). Within the alcohol use disorder cohort, there was a lower prevalence of hyperlipidemia, stroke, ischemic heart disease, congestive heart failure, peripheral artery disease, and COPD than in the non-alcohol use disorder cohort (<xref rid="ref10" ref-type="bibr">10</xref>). Alcohol consumption may impact the adherence to medications for some chronic diseases (<xref rid="ref11" ref-type="bibr">11</xref>). In our study, a more rigorous definition was employed (hospitalization once or outpatient visits three times with ICD codes). Consequently, the lack of follow-up in outpatient tracking may potentially lead to an underestimation of the prevalence of certain diseases.</p><p>The observed findings can be reasonably explained by the dose-dependent effects of alcohol on ACTD. While some studies have shown an increased risk of autoimmune diseases associated with alcohol consumption, others have suggested a protective effect, particularly with low-dose intake (<xref rid="ref12" ref-type="bibr">12</xref>, <xref rid="ref13" ref-type="bibr">13</xref>). A recent study conducted in Denmark reported a higher risk of developing ACTD in patients with alcoholic liver cirrhosis [adjusted incidence rate ratio (aIRR): 1.84; 95% CI: 1.60&#8211;2.12] (<xref rid="ref14" ref-type="bibr">14</xref>). Interestingly, evidence suggests that alcohol may have protective effects against various autoimmune diseases, such as autoimmune thyroid disease, systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis, as observed in both human and animal studies (<xref rid="ref12" ref-type="bibr">12</xref>, <xref rid="ref15" ref-type="bibr">15</xref>&#8211;<xref rid="ref17" ref-type="bibr">17</xref>). However, it is important to note that alcohol exhibits pleiotropic, tissue-specific, and sex-specific anti-inflammatory actions at different doses (<xref rid="ref3" ref-type="bibr">3</xref>). Alcohol can modulate the adaptive immune system in a dose-dependent manner, with chronic moderate consumption leading to T- and B-cell activation and proliferation and chronic heavy consumption associated with T- and B-cell depletion, apoptosis, and increased immunoglobulins (<xref rid="ref5" ref-type="bibr">5</xref>, <xref rid="ref18" ref-type="bibr">18</xref>). Furthermore, excessive alcohol consumption can disrupt the gut barrier, leading to dysbiosis&#8212;an imbalance in gut microbial communities&#8212;which allows the passage of toxins, antigens, and bacteria from the gut lumen into the bloodstream (<xref rid="ref19" ref-type="bibr">19</xref>). This process has the potential to trigger the initiation and progression of autoimmune diseases (<xref rid="ref20" ref-type="bibr">20</xref>).</p><p>Sex- and gender-related differences exist in alcohol consumption (<xref rid="ref21" ref-type="bibr">21</xref>). Findings from multiple countries highlight that men exhibit higher alcohol intake, more frequent drinking habits, and an increased propensity for hazardous drinking than women (<xref rid="ref21" ref-type="bibr">21</xref>). For example, in Taiwan, the prevalence of frequent drinking is approximately six times higher among men (15.1%) than women (2.6%) (<xref rid="ref22" ref-type="bibr">22</xref>). Our study revealed an interesting finding that the association between alcohol abuse and increased risk of ACTD was observed specifically in men, while no such association was found in women. This novel observation can be attributed to sex differences in immune response, organ vulnerability, pregnancy, sex hormones, genetic predisposition, parental inheritance, and epigenetics (<xref rid="ref23" ref-type="bibr">23</xref>). Androgens, for instance, have been associated with decreased immune reactivity and increased threshold for the development of autoimmunity (<xref rid="ref5" ref-type="bibr">5</xref>). It has been reported that alcohol abuse can decrease testosterone levels (<xref rid="ref24" ref-type="bibr">24</xref>), which may contribute to the increased risk of ACTD in men. Additionally, men may have fewer vulnerability factors for ACTD than women, making alcohol abuse a significant contributing factor in their case. However, previous studies have indicated that women exhibit greater sensitivity to the effects of alcohol on inflammatory and immune responses than men (<xref rid="ref5" ref-type="bibr">5</xref>). This difference could be attributed to variations in physiological processing, metabolic clearance of alcohol, and the sensitivity of the nervous system to alcohol (<xref rid="ref5" ref-type="bibr">5</xref>). The topic of sex differences in relation to alcohol and its impact on ACTD is complex and requires further investigation.</p><p>The present study has notable strengths, including its nationwide design and large sample size. However, there are certain limitations that should be acknowledged. First, detailed information regarding alcohol abuse, including the quantity of alcohol consumed, was not available in the NHIRD. This lack of information may introduce confounding factors that could potentially affect the interpretation of the study results. Second, another inherent limitation of utilizing NHIRD lies in the challenge of obtaining socioeconomic status. Despite their investigation relying on insured classification and premium, the precision of these factors in representing income status lacks a solid foundation (<xref rid="ref25" ref-type="bibr">25</xref>). Third, although an association between alcohol abuse and ATCD was identified, the causal relationship between these factors could not be definitively established due to the complex interaction between them and other comorbidities. Fourth, it should be noted that the present findings may not be generalizable to other nations due to differences in race, culture, and medical insurance systems, as well as variations in the impact of alcohol-related genetic factors among different ethnic groups. Fifth, the observed smoking rate among patients with alcohol abuse was low (0.6%), potentially influenced by the stringent diagnostic criteria. Smoking was defined as a diagnosis recorded during at least one hospitalization or three outpatient visits with specific ICD-9-CM (305.1) or ICD-10 (Z72.0) codes. Additionally, the chosen ICD codes often primarily identified patients seeking smoking cessation support. Consequently, these data might underestimate the true prevalence of smoking, indicating a non-differential misclassification bias in both alcohol abuse and non-alcohol abuse cohorts. However, this limitation is not anticipated to impact the outcomes of the study. Therefore, further studies conducted in different nations are warranted to validate these findings.</p></sec><sec sec-type="conclusions" id="sec18"><label>5</label><title>Conclusion</title><p>This population-based cohort study conducted in Taiwan revealed a noteworthy association between alcohol abuse and an increased risk of ACTD in our Asian population, with a particularly strong effect observed among men. The underlying mechanism for this association may be attributed to the dose-dependent impact of alcohol on the immune system. These findings underscore the significance of implementing focused alcohol cessation programs, public health interventions, and lifestyle modifications to prevent the onset of ACTD, especially in individuals with pre-existing conditions such as liver disease, renal disease, CAD, and COPD. However, the precise reason why alcohol abuse appears to affect men more than women in this context remains unclear. Further investigations that include detailed data on alcohol consumption levels, validation in diverse populations, and exploration of sex differences are warranted to validate and expand upon these findings.</p></sec><sec sec-type="data-availability" id="sec19"><title>Data availability statement</title><p>The data used in this study were obtained from the NHIRD published by the Taiwan National Health Insurance Bureau. As per the legal restrictions outlined in the &#8220;Personal Information Protection Act&#8221; imposed by the government of Taiwan, the data cannot be publicly shared. Researchers interested in accessing the data can submit a formal proposal to the NHIRD through their website at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://nhird.nhri.org.tw" ext-link-type="uri">http://nhird.nhri.org.tw</ext-link>.</p></sec><sec sec-type="ethics-statement" id="sec20"><title>Ethics statement</title><p>This study was conducted in accordance with the principles of the Declaration of Helsinki and received approval from the Institutional Review Board of the Chi Mei Medical Center. Written informed consent for participation was not required from the participants or the participants&#8217; legal guardians/next of kin in accordance with the national legislation and institutional requirements.</p></sec><sec sec-type="author-contributions" id="sec21"><title>Author contributions</title><p>C-CC: Conceptualization, Writing &#8211; review &amp; editing. C-TW: Writing &#8211; review &amp; editing. C-HH: Writing &#8211; review &amp; editing. C-CHs: Writing &#8211; review &amp; editing. H-JL: Writing &#8211; review &amp; editing. Y-WC: Writing &#8211; original draft. C-CHu: Writing &#8211; original draft. H-MS: Writing &#8211; review &amp; editing.</p></sec></body><back><fn-group><title>Abbreviations</title><fn fn-type="abbr"><p>ACTD, Autoimmune connective tissue disease; NHIRD, National Health Insurance Research Database; ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification; CAD, Coronary artery disease; CHF, Congestive heart failure; COPD, Chronic obstructive pulmonary disease; AHR, Adjusted hazard ratio; CI, Confidence interval.</p></fn></fn-group><sec sec-type="COI-statement" id="sec23"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="sec100"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="ref1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jog</surname><given-names>NR</given-names></name><name name-style="western"><surname>James</surname><given-names>JA</given-names></name></person-group>. <article-title>Biomarkers in connective tissue diseases</article-title>. <source>J Allergy Clin Immunol</source>. (<year>2017</year>) <volume>140</volume>:<fpage>1473</fpage>&#8211;<lpage>83</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jaci.2017.10.003</pub-id>, PMID: <pub-id pub-id-type="pmid">29221579</pub-id><pub-id pub-id-type="pmcid">PMC5819750</pub-id></mixed-citation></ref><ref id="ref2"><label>2.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Ong</surname><given-names>V.</given-names></name></person-group> Clinical manifestations and diagnosis of mixed connective tissue disease: UpToDate; (<year>2023</year>) <comment>Available at:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-mixed-connective-tissue-disease" ext-link-type="uri">https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-mixed-connective-tissue-disease</ext-link></mixed-citation></ref><ref id="ref3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caslin</surname><given-names>B</given-names></name><name name-style="western"><surname>Mohler</surname><given-names>K</given-names></name><name name-style="western"><surname>Thiagarajan</surname><given-names>S</given-names></name><name name-style="western"><surname>Melamed</surname><given-names>E</given-names></name></person-group>. <article-title>Alcohol as friend or foe in autoimmune diseases: a role for gut microbiome?</article-title><source>Gut Microbes</source>. (<year>2021</year>) <volume>13</volume>:<fpage>1916278</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19490976.2021.1916278</pub-id>, PMID: <pub-id pub-id-type="pmid">34224314</pub-id><pub-id pub-id-type="pmcid">PMC8259720</pub-id></mixed-citation></ref><ref id="ref4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sudhinaraset</surname><given-names>M</given-names></name><name name-style="western"><surname>Wigglesworth</surname><given-names>C</given-names></name><name name-style="western"><surname>Takeuchi</surname><given-names>DT</given-names></name></person-group>. <article-title>Social and cultural contexts of alcohol use: influences in a social-ecological framework</article-title>. <source>Alcohol Res</source>. (<year>2016</year>) <volume>38</volume>:<fpage>35</fpage>&#8211;<lpage>45</lpage>. PMID: <pub-id pub-id-type="pmid">27159810</pub-id><pub-id pub-id-type="pmcid">PMC4872611</pub-id></mixed-citation></ref><ref id="ref5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romeo</surname><given-names>J</given-names></name><name name-style="western"><surname>Warnberg</surname><given-names>J</given-names></name><name name-style="western"><surname>Nova</surname><given-names>E</given-names></name><name name-style="western"><surname>Diaz</surname><given-names>LE</given-names></name><name name-style="western"><surname>Gomez-Martinez</surname><given-names>S</given-names></name><name name-style="western"><surname>Marcos</surname><given-names>A</given-names></name></person-group>. <article-title>Moderate alcohol consumption and the immune system: a review</article-title>. <source>Br J Nutr</source>. (<year>2007</year>) <volume>98</volume>:<fpage>S111</fpage>&#8211;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.1017/S0007114507838049</pub-id>, PMID: <pub-id pub-id-type="pmid">17922947</pub-id></mixed-citation></ref><ref id="ref6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Volpato</surname><given-names>S</given-names></name><name name-style="western"><surname>Pahor</surname><given-names>M</given-names></name><name name-style="western"><surname>Ferrucci</surname><given-names>L</given-names></name><name name-style="western"><surname>Simonsick</surname><given-names>EM</given-names></name><name name-style="western"><surname>Guralnik</surname><given-names>JM</given-names></name><name name-style="western"><surname>Kritchevsky</surname><given-names>SB</given-names></name><etal/></person-group>. <article-title>Relationship of alcohol intake with inflammatory markers and plasminogen activator inhibitor-1 in well-functioning older adults: the health, aging, and body composition study</article-title>. <source>Circulation</source>. (<year>2004</year>) <volume>109</volume>:<fpage>607</fpage>&#8211;<lpage>12</lpage>. doi: <pub-id pub-id-type="doi">10.1161/01.CIR.0000109503.13955.00</pub-id>, PMID: <pub-id pub-id-type="pmid">14769682</pub-id></mixed-citation></ref><ref id="ref7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sung</surname><given-names>SF</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>CY</given-names></name><name name-style="western"><surname>Hu</surname><given-names>YH</given-names></name></person-group>. <article-title>Two decades of research using Taiwan&#8217;s National Health Insurance Claims Data: bibliometric and text mining analysis on PubMed</article-title>. <source>J Med Internet Res</source>. (<year>2020</year>) <volume>22</volume>:<fpage>e18457</fpage>. doi: <pub-id pub-id-type="doi">10.2196/18457</pub-id>, PMID: <pub-id pub-id-type="pmid">32543443</pub-id><pub-id pub-id-type="pmcid">PMC7327589</pub-id></mixed-citation></ref><ref id="ref8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>MC</given-names></name><name name-style="western"><surname>Yu</surname><given-names>CH</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CT</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CC</given-names></name><name name-style="western"><surname>Shen</surname><given-names>WW</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CH</given-names></name></person-group>. <article-title>Prevalence and identification of alcohol use disorders among severe mental illness inpatients in Taiwan</article-title>. <source>Psychiatry Clin Neurosci</source>. (<year>2009</year>) <volume>63</volume>:<fpage>94</fpage>&#8211;<lpage>100</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1440-1819.2008.01909.x</pub-id>, PMID: <pub-id pub-id-type="pmid">19154215</pub-id></mixed-citation></ref><ref id="ref9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>CC</given-names></name><name name-style="western"><surname>Ho</surname><given-names>CH</given-names></name><name name-style="western"><surname>Chen</surname><given-names>YC</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>CC</given-names></name><name name-style="western"><surname>Lin</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>JJ</given-names></name><etal/></person-group>. <article-title>Autoimmune connective tissue disease following carbon monoxide poisoning: a Nationwide population-based cohort study</article-title>. <source>Clin Epidemiol</source>. (<year>2020</year>) <volume>12</volume>:<fpage>1287</fpage>&#8211;<lpage>98</lpage>. doi: <pub-id pub-id-type="doi">10.2147/CLEP.S266396</pub-id>, PMID: <pub-id pub-id-type="pmid">33262659</pub-id><pub-id pub-id-type="pmcid">PMC7686473</pub-id></mixed-citation></ref><ref id="ref10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>CF</given-names></name><name name-style="western"><surname>Kao</surname><given-names>WT</given-names></name><name name-style="western"><surname>Liu</surname><given-names>KT</given-names></name><name name-style="western"><surname>Chen</surname><given-names>SL</given-names></name><name name-style="western"><surname>Huang</surname><given-names>YT</given-names></name><name name-style="western"><surname>Huang</surname><given-names>CC</given-names></name></person-group>. <article-title>Alcohol use disorders associated with an increased risk of mesenteric ischemia: a nationwide cohort study</article-title>. <source>Drug Alcohol Depend</source>. (<year>2019</year>) <volume>194</volume>:<fpage>264</fpage>&#8211;<lpage>70</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2018.10.030</pub-id>, PMID: <pub-id pub-id-type="pmid">30469097</pub-id></mixed-citation></ref><ref id="ref11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grodensky</surname><given-names>CA</given-names></name><name name-style="western"><surname>Golin</surname><given-names>CE</given-names></name><name name-style="western"><surname>Ochtera</surname><given-names>RD</given-names></name><name name-style="western"><surname>Turner</surname><given-names>BJ</given-names></name></person-group>. <article-title>Systematic review: effect of alcohol intake on adherence to outpatient medication regimens for chronic diseases</article-title>. <source>J Stud Alcohol Drugs</source>. (<year>2012</year>) <volume>73</volume>:<fpage>899</fpage>&#8211;<lpage>910</lpage>. doi: <pub-id pub-id-type="doi">10.15288/jsad.2012.73.899</pub-id>, PMID: <pub-id pub-id-type="pmid">23036207</pub-id><pub-id pub-id-type="pmcid">PMC9798466</pub-id></mixed-citation></ref><ref id="ref12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Azizov</surname><given-names>V</given-names></name><name name-style="western"><surname>Zaiss</surname><given-names>MM</given-names></name></person-group>. <article-title>Alcohol consumption in rheumatoid arthritis: a path through the immune system</article-title>. <source>Nutrients</source>. (<year>2021</year>) <volume>13</volume>:<fpage>324</fpage>. doi: <pub-id pub-id-type="doi">10.3390/nu13041324</pub-id>, PMID: <pub-id pub-id-type="pmid">33923766</pub-id><pub-id pub-id-type="pmcid">PMC8072698</pub-id></mixed-citation></ref><ref id="ref13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Manouchehrinia</surname><given-names>A</given-names></name><name name-style="western"><surname>Olsson</surname><given-names>T</given-names></name><name name-style="western"><surname>Alfredsson</surname><given-names>L</given-names></name><name name-style="western"><surname>Kockum</surname><given-names>I</given-names></name></person-group>. <article-title>Alcohol consumption and risk of common autoimmune inflammatory diseases-evidence from a large-scale genetic analysis totaling 1 million individuals</article-title>. <source>Front Genet</source>. (<year>2021</year>) <volume>12</volume>:<fpage>687745</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fgene.2021.687745</pub-id>, PMID: <pub-id pub-id-type="pmid">34239545</pub-id><pub-id pub-id-type="pmcid">PMC8258244</pub-id></mixed-citation></ref><ref id="ref14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gronbaek</surname><given-names>L</given-names></name><name name-style="western"><surname>Vilstrup</surname><given-names>H</given-names></name><name name-style="western"><surname>Deleuran</surname><given-names>B</given-names></name><name name-style="western"><surname>Wiest</surname><given-names>R</given-names></name><name name-style="western"><surname>Krag</surname><given-names>A</given-names></name><name name-style="western"><surname>Jepsen</surname><given-names>P</given-names></name></person-group>. <article-title>Alcoholic cirrhosis increases risk for autoimmune diseases: a Nationwide registry-based cohort study</article-title>. <source>Clin Gastroenterol Hepatol</source>. (<year>2015</year>) <volume>13</volume>:<fpage>2017</fpage>&#8211;<lpage>22</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cgh.2015.05.032</pub-id>, PMID: <pub-id pub-id-type="pmid">26044312</pub-id></mixed-citation></ref><ref id="ref15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di Giuseppe</surname><given-names>D</given-names></name><name name-style="western"><surname>Alfredsson</surname><given-names>L</given-names></name><name name-style="western"><surname>Bottai</surname><given-names>M</given-names></name><name name-style="western"><surname>Askling</surname><given-names>J</given-names></name><name name-style="western"><surname>Wolk</surname><given-names>A</given-names></name></person-group>. <article-title>Long term alcohol intake and risk of rheumatoid arthritis in women: a population based cohort study</article-title>. <source>BMJ</source>. (<year>2012</year>) <volume>345</volume>:<fpage>e4230</fpage>. doi: <pub-id pub-id-type="doi">10.1136/bmj.e4230</pub-id>, PMID: <pub-id pub-id-type="pmid">22782847</pub-id><pub-id pub-id-type="pmcid">PMC3393782</pub-id></mixed-citation></ref><ref id="ref16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Effraimidis</surname><given-names>G</given-names></name><name name-style="western"><surname>Tijssen</surname><given-names>JG</given-names></name><name name-style="western"><surname>Wiersinga</surname><given-names>WM</given-names></name></person-group>. <article-title>Alcohol consumption as a risk factor for autoimmune thyroid disease: a prospective study</article-title>. <source>Eur Thyroid J</source>. (<year>2012</year>) <volume>1</volume>:<fpage>99</fpage>&#8211;<lpage>104</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000338920</pub-id>, PMID: <pub-id pub-id-type="pmid">24783003</pub-id><pub-id pub-id-type="pmcid">PMC3821464</pub-id></mixed-citation></ref><ref id="ref17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hedstrom</surname><given-names>AK</given-names></name><name name-style="western"><surname>Hillert</surname><given-names>J</given-names></name><name name-style="western"><surname>Olsson</surname><given-names>T</given-names></name><name name-style="western"><surname>Alfredsson</surname><given-names>L</given-names></name></person-group>. <article-title>Alcohol as a modifiable lifestyle factor affecting multiple sclerosis risk</article-title>. <source>JAMA Neurol</source>. (<year>2014</year>) <volume>71</volume>:<fpage>300</fpage>&#8211;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamaneurol.2013.5858</pub-id>, PMID: <pub-id pub-id-type="pmid">24395432</pub-id></mixed-citation></ref><ref id="ref18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slukvin</surname><given-names>II</given-names></name><name name-style="western"><surname>Jerrells</surname><given-names>TR</given-names></name></person-group>. <article-title>Different pathways of in vitro ethanol-induced apoptosis in thymocytes and splenic T and B lymphocytes</article-title>. <source>Immunopharmacology</source>. (<year>1995</year>) <volume>31</volume>:<fpage>43</fpage>&#8211;<lpage>57</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0162-3109(95)00032-4</pub-id>, PMID: <pub-id pub-id-type="pmid">8655290</pub-id></mixed-citation></ref><ref id="ref19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>AW</given-names></name><name name-style="western"><surname>Fouts</surname><given-names>DE</given-names></name><name name-style="western"><surname>Brandl</surname><given-names>J</given-names></name><name name-style="western"><surname>Starkel</surname><given-names>P</given-names></name><name name-style="western"><surname>Torralba</surname><given-names>M</given-names></name><name name-style="western"><surname>Schott</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Enteric dysbiosis associated with a mouse model of alcoholic liver disease</article-title>. <source>Hepatology</source>. (<year>2011</year>) <volume>53</volume>:<fpage>96</fpage>&#8211;<lpage>105</lpage>. doi: <pub-id pub-id-type="doi">10.1002/hep.24018</pub-id>, PMID: <pub-id pub-id-type="pmid">21254165</pub-id><pub-id pub-id-type="pmcid">PMC3059122</pub-id></mixed-citation></ref><ref id="ref20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Kirby</surname><given-names>J</given-names></name><name name-style="western"><surname>Reilly</surname><given-names>CM</given-names></name><name name-style="western"><surname>Luo</surname><given-names>XM</given-names></name></person-group>. <article-title>Leaky gut as a danger signal for autoimmune diseases</article-title>. <source>Front Immunol</source>. (<year>2017</year>) <volume>8</volume>:<fpage>598</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2017.00598</pub-id>, PMID: <pub-id pub-id-type="pmid">28588585</pub-id><pub-id pub-id-type="pmcid">PMC5440529</pub-id></mixed-citation></ref><ref id="ref21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Erol</surname><given-names>A</given-names></name><name name-style="western"><surname>Karpyak</surname><given-names>VM</given-names></name></person-group>. <article-title>Sex and gender-related differences in alcohol use and its consequences: contemporary knowledge and future research considerations</article-title>. <source>Drug Alcohol Depend</source>. (<year>2015</year>) <volume>156</volume>:<fpage>1</fpage>&#8211;<lpage>13</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2015.08.023</pub-id>, PMID: <pub-id pub-id-type="pmid">26371405</pub-id></mixed-citation></ref><ref id="ref22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chuang</surname><given-names>YC</given-names></name><name name-style="western"><surname>Chuang</surname><given-names>KY</given-names></name></person-group>. <article-title>Gender differences in relationships between social capital and individual smoking and drinking behavior in Taiwan</article-title>. <source>Soc Sci Med</source>. (<year>2008</year>) <volume>67</volume>:<fpage>1321</fpage>&#8211;<lpage>30</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.socscimed.2008.06.033</pub-id>, PMID: <pub-id pub-id-type="pmid">18667260</pub-id></mixed-citation></ref><ref id="ref23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ngo</surname><given-names>ST</given-names></name><name name-style="western"><surname>Steyn</surname><given-names>FJ</given-names></name><name name-style="western"><surname>McCombe</surname><given-names>PA</given-names></name></person-group>. <article-title>Gender differences in autoimmune disease</article-title>. <source>Front Neuroendocrinol</source>. (<year>2014</year>) <volume>35</volume>:<fpage>347</fpage>&#8211;<lpage>69</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.yfrne.2014.04.004</pub-id><pub-id pub-id-type="pmid">24793874</pub-id></mixed-citation></ref><ref id="ref24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maneesh</surname><given-names>M</given-names></name><name name-style="western"><surname>Dutta</surname><given-names>S</given-names></name><name name-style="western"><surname>Chakrabarti</surname><given-names>A</given-names></name><name name-style="western"><surname>Vasudevan</surname><given-names>DM</given-names></name></person-group>. <article-title>Alcohol abuse-duration dependent decrease in plasma testosterone and antioxidants in males</article-title>. <source>Indian J Physiol Pharmacol</source>. (<year>2006</year>) <volume>50</volume>:<fpage>291</fpage>&#8211;<lpage>6</lpage>. PMID: <pub-id pub-id-type="pmid">17193902</pub-id></mixed-citation></ref><ref id="ref25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsu</surname><given-names>Y-C</given-names></name></person-group>. <article-title>Analyzing Taiwan&#8217;s National Health Insurance Research Database to explicate the allocation of health-care resources</article-title>. <source>Adv Digest Med</source>. (<year>2015</year>) <volume>2</volume>:<fpage>41</fpage>&#8211;<lpage>3</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.aidm.2015.04.001</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>